Are There Any Connections between Language Deficits and Cognitive Slowing in Alzheimer's DiseaseSchecker M.c · Kochler C.c · Schmidtke K.b · Rauh R.a
aKlinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter, Universität Freiburg, Freiburg, bKlinik für Hirnleistungsstörungen Klausenbach, Nordrach, and cNeurolinguistisches Labor NLL, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter, Universität Freiburg, Freiburg, Germany
Prof. Dr. Michael Schecker
Neurolinguistisches Labor NLL, Klinik für Psychiatrie, Psychotherapie und
Psychosomatik im Kindes- und Jugendalter, Universität Freiburg
Hauptstrasse 1, DE-79104 Freiburg (Germany)
Do you have an account?
Background: Speech disorders already occur in the early phases of Alzheimer's disease (AD). As a possible cause, problems of executive processes are discussed. Cognitive slowing is also repeatedly addressed. Aims: Are there any connections between cognitive slowing and speech disorders in AD? And is there a relationship between cognitive slowing and executive processes? Methods: The data of 72 healthy controls and 52 AD patients were examined with regard to their language performance and their response times in a computerized Stroop paradigm. Results: The AD patients showed significantly worse results in all language tests as well as much longer reaction times in all Stroop conditions, especially in the interference condition (Stroop 3). Speech errors and response times correlated with severity (MMSE), and the speech errors correlated with the reaction times in Stroop 3 (interference condition, which reflects the processing time of executive processes). Conclusion: The most interesting question now is: How are language processing and executive processing time (Stroop 3) related?
© 2014 S. Karger AG, Basel
Article / Publication Details
Open Access License / Drug Dosage / DisclaimerOpen Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.